The company manufactures and trades structural steel products like angles, channels, and bars used in construction and infrastructure projects, primarily serving government power utilities and private industrial clients.
The company operates in a highly fragmented, commodity-driven industry where products must meet standard BIS specifications, leaving little room for differentiation. While average ROCE is 13.5%, the razor-thin net margin of 1.1% indicates a lack of pricing power and vulnerability to raw material cost fluctuations.
Management has prioritized growth through an IPO to fund working capital and debt repayment, but the high reliance on unsecured business loans at interest rates up to 17% suggests inefficient historical capital sourcing. Reinvestment has resulted in low revenue growth relative to the capital employed.
The business collapsed as the razor-thin 1.1% net margin was completely erased by a minor uptick in raw material costs, which the company could not pass on due to its commodity-grade product. While management extracted massive pay raises, the cash conversion remained abysmal, forcing the company to cycle through increasingly expensive unsecured debt to fund basic operations. Eventually, the practice of funneling interest-free loans to third parties while paying 17% interest on its own borrowings led to a liquidity crisis that wiped out equity holders.
RichFakir rates Mittal Sections Ltd's business quality as poor — 27/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mittal Sections Ltd is trading about 38% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mittal Sections Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mittal Sections Ltd's fair value is about ₹39 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →